Aquestive Therapeutics (NASDAQ:AQST) Director Sells $125,500.00 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Director Julie Krop sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total value of $125,500.00. Following the completion of the transaction, the director owned 25,000 shares in the company, valued at approximately $125,500. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock traded up $0.14 during mid-day trading on Wednesday, reaching $5.17. The stock had a trading volume of 1,004,140 shares, compared to its average volume of 3,172,293. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.93 and a fifty-two week high of $7.55. The stock’s 50-day simple moving average is $4.20 and its 200-day simple moving average is $4.41. The firm has a market capitalization of $647.95 million, a PE ratio of -8.40 and a beta of 1.46.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, May 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. The firm had revenue of $14.45 million for the quarter, compared to analyst estimates of $10.90 million. On average, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on AQST shares. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Oppenheimer started coverage on Aquestive Therapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $8.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $8.50.

Hedge Funds Weigh In On Aquestive Therapeutics

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Aquestive Therapeutics by 30.8% in the third quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock valued at $31,651,000 after purchasing an additional 1,333,627 shares during the last quarter. Federated Hermes Inc. boosted its holdings in Aquestive Therapeutics by 159.4% during the fourth quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock worth $13,132,000 after purchasing an additional 1,249,044 shares during the last quarter. Bank of America Corp DE grew its position in Aquestive Therapeutics by 99.2% in the 1st quarter. Bank of America Corp DE now owns 2,405,050 shares of the company’s stock worth $9,981,000 after purchasing an additional 1,197,459 shares in the last quarter. BNP Paribas Financial Markets grew its position in Aquestive Therapeutics by 6,233.4% in the 4th quarter. BNP Paribas Financial Markets now owns 1,171,675 shares of the company’s stock worth $7,569,000 after purchasing an additional 1,153,175 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in Aquestive Therapeutics by 804.6% in the 4th quarter. Wells Fargo & Company MN now owns 1,188,531 shares of the company’s stock valued at $7,678,000 after buying an additional 1,057,145 shares during the last quarter. 32.45% of the stock is owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.